Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

UNICEF: Children And Women Displaced By Conflict In Pakistan Need Urgent And Ongoing Support
UNICEF is deeply concerned about the condition of thousands of children who have been displaced by conflict, or who remain in affected areas, in north-western Pakistan. Nearly 50 per cent of the estimated 2 million displaced are children, many of whom are in urgent need of health and educational services, nutritional support, access to clean water and sanitation as well as protection. Their situation has been compounded by the harsh summer temperatures.
generic viagra online
The Journal "Foot & Ankle Specialist" Accepted In Medline
Foot & Ankle Specialist (FAS), published by SAGE, has been accepted for inclusion in MEDLINE, the premier bibliographic database of the U.S. National Library of Medicine (NLM), containing more than 16 million journal article citations.
News of the day
Abbott And AstraZeneca Submit New Drug Application To The FDA For CERTRIAD™, An Investigational Treatment For Mixed Dyslipidemia
Abbott Park, Illinois (NYSE: ABT) and London, UK - Abbott and AstraZeneca announced that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL- cholesterol (the "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). The NDA submission for this investigational compound, containing the active ingredients of CRESTOR® (rosuvastatin calcium) and TRILIPIX® (fenofibric acid), is supported by data from multiple studies, including efficacy and safety studies with the 5mg, 10mg and 20mg doses of rosuvastatin combined with fenofibric acid. Pending approval of the NDA, the treatment will be marketed as CERTRIAD™.
Health Insurance

Improving Care For Cardiac Patients Is Centerpiece Of American Society Of Nuclear Cardiology Meeting

The American Society of Nuclear Cardiology will host its 14th Annual Scientific Session October 1 - 4, 2009 in Minneapolis, MN. Imaging specialists from around the world will gather at ASNC2009 to discuss the meeting"s theme - "Quality and Patient-Centered Outcomes in Cardiac Imaging." With original scientific abstract poster sessions, dynamic lectures, and late-breaking clinical trial presentations, the ASNC Annual Scientific Session is critical to advancing best practices and new research in the field of cardiovascular imaging. More than 1,000 physicians, scientists, technologists, and nurses will attend this year"s meeting, which will feature lectures from esteemed faculty such as Dr. Manuel Cerqueira of the Cleveland Clinic, Dr. Robert Bonow of the Mayo Clinic, and Dr. Jack Lewin of the American College of Cardiology. "It is an exciting time for cardiovascular imaging," said ASNC President Jennifer Mieres, MD, FASNC. "ASNC2009 showcases how far we"ve come as a profession and the new research and technology that are helping advance our field and enable us to provide optimal care to our patients. We have been working diligently to improve efficacy and patient outcomes of cardiovascular imaging. This conference provides us with an opportunity to step back, assess the progress we"ve made, and identify and discuss the challenges that remain." The American Society of Nuclear Cardiology (ASNC) is the leader in education, advocacy, and quality for the field of nuclear cardiology. Serving more than 5,000 individuals in over 50 countries, ASNC is the only professional association dedicated to the dynamic subspecialty of nuclear cardiology. American Society of Nuclear Cardiology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009